ABT and BSX Related Headlines
Go Back- Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
- Defensive stocks show deep value as cyclicals run hot, UBS says
- Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'
- Oppenheimer sees stronger growth at Boston Scientific
- UBS: Time to cut back on cyclicals, favor select defensives
- This MedTech stock is 'a strong buy under $500': Bernstein
- Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings
